Proyectos

MIRACLE is a European project.

Early-stage non small cell lung cancer (ES-NSCLC) represents 20-30% of all NSCLC and is characterized by a high survival rate after surgery. However, there is variability in clinical outcomes among patients sharing the same disease stage, suggesting that other factors could determine the risk of relapse. Accurate and validated tools to stratify patients according to their risk of relapse are still lacking. Hypothesis: We hypothesize that multiple factors could influence the prognosis of resected ES-NSCLC patients. In particular, tumor tissue and microenvironment (TME) characteristics, liquid biopsy, radiomics features and clinical-pathological factors could all be involved. Aims: Primary: Development of a machine learning (ML) algorithm acting as a clinical decision support tool for disease free survival (DFS) prediction and patient stratification based on joint analysis of biological, clinical and radiologic features on a training cohort of resected ES-NSCLC. Secondary: Validation of the developed algorithm on an independent cohort.